{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:23:26Z","timestamp":1790789006952,"version":"4.1.0"},"reference-count":77,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Central Lancashire, UK"},{"name":"Cherry Marketing Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Aims: Ulcerative colitis (UC) significantly impacts individuals\u2019 self-perception, body image, and overall quality of life, while also imposing considerable economic costs. These challenges highlight the necessity for complementary therapeutic strategies with reduced adverse effects to support conventional pharmacological treatments. Among natural interventions, Montmorency tart cherries, noted for their high anthocyanin content have emerged as a natural anti-inflammatory agent for UC. The current trial aimed to investigate the effects of Montmorency tart cherries compared to placebo in patients with mild to moderate UC. Materials and methods: Thirty-five patients with UC were randomly assigned to receive either placebo or Montmorency tart cherry juice, of which they drank 60 mL per day for 6 weeks. The primary outcomes and health-related quality of life, measured via the Inflammatory Bowel Disease Quality of Life Questionnaire (IBDQ), and the secondary measures, including other health-related questionnaires, blood biomarkers, and faecal samples, were measured before and after the intervention. Linear mixed-effects models were adopted to contrast the changes from baseline to 6 weeks between trial arms. Effect sizes were calculated using Cohen\u2019s d. Results: There were significantly greater improvements in the IBDQ (22.61 (95% CI = 5.24 to 39.99) d = 0.90) and simple clinical colitis activity index (\u22123.98 (95% CI = \u22126.69 to \u20131.28) d = \u22121.01) in the tart cherry trial arm compared to placebo. In addition, reductions in faecal calprotectin levels were significantly greater in the tart cherry trial arm compared to placebo (\u2212136.17 \u00b5g\/g (95% CI = \u2212258.06 to \u20134.28) d = \u22121.14). Loss to follow-up (N = 1) and adverse events (N = 1) were low and compliance was very high in the tart cherry (95.8%) trial arm. Conclusions: Given the profoundly negative effects of UC on health-related quality of life and its fiscal implications for global healthcare systems, this trial indicates that twice-daily tart cherry supplementation can improve IBD-related quality of life as well as the severity of symptoms and therefore may be important in the management of UC.<\/jats:p>","DOI":"10.3390\/life15020306","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T07:48:22Z","timestamp":1739778502000},"page":"306","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis; A Placebo Randomized Controlled Trial"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2231-3732","authenticated-orcid":false,"given":"Jonathan","family":"Sinclair","sequence":"first","affiliation":[{"name":"Research Centre for Applied Sport, Physical Activity and Performance, School of Health Social Work & Sport, University of Central Lancashire, Preston PR1 2HE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Allan","sequence":"additional","affiliation":[{"name":"Research Centre for Applied Sport, Physical Activity and Performance, School of Health Social Work & Sport, University of Central Lancashire, Preston PR1 2HE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Brooks-Warburton","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"},{"name":"Gastroenterology Department, Lister Hospital, Stevenage SG1 4AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lawson","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Goh","sequence":"additional","affiliation":[{"name":"Department of Clinical, Pharmaceutical and Biological Science, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terun","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Surgery & Interventional Science, University College London, London WC1E 6BT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-3764","authenticated-orcid":false,"given":"Lindsay","family":"Bottoms","sequence":"additional","affiliation":[{"name":"School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis. Mon."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Freeman, K., Ryan, R., Parsons, N., Taylor-Phillips, S., Willis, B.H., and Clarke, A. (2021). The incidence and prevalence of inflammatory bowel disease in UK primary care: A retrospective cohort study of the IQVIA Medical Research Database. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01716-6"},{"key":"ref_4","first-page":"33","article-title":"Inflammatory bowel disease: An expanding global health problem","volume":"6","year":"2013","journal-title":"Clin. Med. Insights Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/ibd.21878","article-title":"Direct medical cost of managing IBD patients: A Canadian population-based study","volume":"18","author":"Bernstein","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/apt.15033","article-title":"Systematic review: Predictive biomarkers of therapeutic response in inflammatory bowel disease\u2014Personalised medicine in its infancy","volume":"48","author":"Stevens","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/ecco-jcc\/jjz081","article-title":"A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986\u20132015","volume":"13","author":"Park","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/14737167.6.4.471","article-title":"Economic burden of inflammatory bowel disease: A UK perspective","volume":"6","author":"Luces","year":"2006","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40273-017-0601-6","article-title":"A systematic review of the cost-effectiveness of biologics for ulcerative colitis","volume":"36","author":"Stawowczyk","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/01.mib.0000179467.01748.99","article-title":"Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: Psychometric assessments and a comparison with general population norms","volume":"11","author":"Bernklev","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.cgh.2006.09.027","article-title":"The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life","volume":"4","author":"Graff","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ilar\/ilv030","article-title":"The intestinal microbiota in inflammatory bowel disease","volume":"56","author":"Becker","year":"2015","journal-title":"ILAR J."},{"key":"ref_13","first-page":"1064","article-title":"Work losses related to inflammatory bowel disease in the United States: Results from the National Health Interview Survey","volume":"98","author":"Longobardi","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.crohns.2012.07.010","article-title":"Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis\u2014An open pilot study","volume":"7","author":"Biedermann","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ibd.20297","article-title":"Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update","volume":"14","author":"Rubin","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/gut.49.6.783","article-title":"Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses","volume":"49","author":"Kruis","year":"2001","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.18632\/oncotarget.13894","article-title":"Looking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds","volume":"8","author":"Chumanevich","year":"2016","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: A meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s10620-006-9622-2","article-title":"Oxidative stress and pathogenesis of inflammatory bowel disease: An. epiphenomenon or the cause?","volume":"52","author":"Rezaie","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01538126","article-title":"Neutrophil-mediated mucosal injury: Role of reactive oxygen metabolites","volume":"33","author":"Grisham","year":"1988","journal-title":"Dig. Dis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0891-5849(92)90079-V","article-title":"Oxygen radicals in ulcerative colitis","volume":"13","author":"Babbs","year":"1992","journal-title":"Free Radic. Biol. Med."},{"key":"ref_22","first-page":"1904","article-title":"A pilot study to evaluate the safety and efficacy of an oral dose of (\u2212)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis","volume":"19","author":"Dryden","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hills, R.D., Pontefract, B.A., Mishcon, H.R., Black, C.A., Sutton, S.C., and Theberge, C.R. (2019). Gut microbiome: Profound implications for diet and disease. Nutrients, 11.","DOI":"10.3390\/nu11071613"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/carcin\/bgq248","article-title":"Anti-inflammatory effects of freeze-dried black raspberry powder in ulcerative colitis","volume":"32","author":"Montrose","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1361779","DOI":"10.1080\/16546628.2017.1361779","article-title":"Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits","volume":"61","author":"Khoo","year":"2017","journal-title":"Food Nutr. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Roth, S., Spalinger, M.R., Gottier, C., Biedermann, L., Zeitz, J., Lang, S., Weber, A., Rogler, G., and Scharl, M. (2016). Bilberry-derived anthocyanins modulate cytokine expression in the intestine of patients with ulcerative colitis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154817"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mnfr.201100380","article-title":"Bilberries and their anthocyanins ameliorate experimental colitis","volume":"55","author":"Piberger","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.foodchem.2018.04.047","article-title":"Phytochemical and physical properties of blueberries, tart cherries, strawberries, and cranberries as affected by different drying methods","volume":"262","author":"Nemzer","year":"2018","journal-title":"Food Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jnutbio.2018.04.001","article-title":"Impact of tart cherries polyphenols on the human gut microbiota and phenolic metabolites in vitro and in vivo","volume":"59","author":"Pottgen","year":"2018","journal-title":"J. Nutr. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ibd\/izy281","article-title":"Bacteroides thetaiotaomicron ameliorates colon inflammation in preclinical models of Crohn\u2019s disease","volume":"25","author":"Delday","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s11332-022-00901-8","article-title":"Perceptions, beliefs and behaviors of nutritional and supplementary practices in inflammatory bowel disease","volume":"18","author":"Sinclair","year":"2022","journal-title":"Sport Sci. Health"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sinclair, J., Dillon, S., Allan, R., Brooks-Warburton, J., Desai, T., Lawson, C., and Bottoms, L. (2023). Health benefits of Montmorency tart cherry juice supplementation in adults with mild to moderate ulcerative colitis: A protocol for a placebo randomized controlled trial. Methods Protoc., 6.","DOI":"10.3390\/mps6050076"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10787-019-00595-4","article-title":"A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn\u2019s disease","volume":"27","author":"Bjarnason","year":"2019","journal-title":"Inflammopharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s11130-014-0409-x","article-title":"Effect of a tart cherry juice supplement on arterial stiffness and inflammation in healthy adults: A randomised controlled trial","volume":"69","author":"Lynn","year":"2014","journal-title":"Plant Foods Hum. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s11332-022-00973-6","article-title":"The efficacy of a tart cherry drink for the treatment of patellofemoral pain in recreationally active individuals: A placebo randomized control trial","volume":"18","author":"Sinclair","year":"2022","journal-title":"Sport Sci. Health"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kimble, R., Keane, K.M., Lodge, J.K., and Howatson, G. (2021). The influence of tart cherry (Prunus cerasus, cv Montmorency) concentrate supplementation for 3 months on cardiometabolic risk factors in middle-aged adults: A randomised, placebo-controlled trial. Nutrients, 13.","DOI":"10.3390\/nu13051417"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hillman, A.R., and Chrismas, B.C. (2021). Thirty days of Montmorency tart cherry supplementation has no effect on gut microbiome composition, inflammation, or glycemic control in healthy adults. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.733057"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jff.2019.04.005","article-title":"Effects of Montmorency tart cherry supplementation on cardiometabolic markers in metabolic syndrome participants: A pilot study","volume":"57","author":"Desai","year":"2019","journal-title":"J. Funct. Foods"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sinclair, J., Dillon, S., Lowe, N.M., and Melia, A. (2023). Effects of a nutrition education programme in stage IV cardiac rehabilitation patients: A 3-arm randomised controlled trial. Life, 14.","DOI":"10.3390\/life14010063"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sinclair, J., Bottoms, L., Dillon, S., Allan, R., Shadwell, G., and Butters, B. (2022). Effects of Montmorency tart cherry and blueberry juice on cardiometabolic and other health-related outcomes: A three-arm placebo randomized controlled trial. Int. J. Environ. Res. Public. Health, 19.","DOI":"10.3390\/ijerph19095317"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00394-011-0263-7","article-title":"Effect of tart cherry juice (Prunus cerasus) on melatonin levels and enhanced sleep quality","volume":"51","author":"Howatson","year":"2012","journal-title":"Eur. J. Nutr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1039\/C9FO00913B","article-title":"Effect of Montmorency tart cherry juice on cognitive performance in older adults: A randomized controlled trial","volume":"10","author":"Chai","year":"2019","journal-title":"Food Funct."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00004872-200305000-00001","article-title":"European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory, and home blood pressure measurement","volume":"21","author":"Asmar","year":"2003","journal-title":"J. Hypertens."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/0016-5085(89)90905-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.crohns.2012.07.012","article-title":"Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors","volume":"7","author":"Moradkhani","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/ibd\/izad282","article-title":"Systematic literature review of the ability of the IBDQ-32 to detect meaningful change in ulcerative colitis health indicators","volume":"30","author":"Dubinsky","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ibd\/izaa201","article-title":"The IBD-F patient self-assessment scale accurately depicts the level of fatigue and predicts a negative effect on the quality of life of patients with IBD in clinical remission","volume":"27","author":"Varbobitis","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"107087","DOI":"10.1016\/j.rmed.2022.107087","article-title":"Test-retest reliability, agreement, and construct validity of the International Physical Activity Questionnaire short-form (IPAQ-sf) in people with COPD","volume":"206","author":"Flora","year":"2023","journal-title":"Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the Hospital Anxiety and Depression Scale: An updated literature review","volume":"52","author":"Bjelland","year":"2002","journal-title":"J. Psychosom. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1590-8658(03)00381-5","article-title":"Role of faecal calprotectin as a non-invasive marker of intestinal inflammation","volume":"35","author":"Costa","year":"2003","journal-title":"Dig. Liver Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"704953","DOI":"10.1155\/2012\/704953","article-title":"The role of bacteria in the pathogenesis of ulcerative colitis","volume":"2012","author":"Sasaki","year":"2012","journal-title":"J. Signal Transduct."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/1751-2980.12849","article-title":"Gut microbiota in ulcerative colitis: Insights on pathogenesis and treatment","volume":"21","author":"Guo","year":"2020","journal-title":"J. Dig. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00248-021-01789-6","article-title":"Spatial characteristics of colonic mucosa-associated gut microbiota in humans","volume":"83","author":"Jiao","year":"2022","journal-title":"Microb. Ecol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Simmonds, S.E., Ly, L., Lim, R., Morse, T., Thakku, S.G., Rosario Cora, K., and Kalantar, K. (2024). CZ ID: A cloud-based, no-code platform enabling advanced long-read metagenomic analysis. bioRxiv.","DOI":"10.1101\/2024.02.29.579666"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"McMurdie, P.J., and Holmes, S.H. (2013). phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061217"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15.","DOI":"10.1186\/s13059-014-0550-8"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Davis, N.M., Proctor, D.M., Holmes, S.P., Relman, D.A., and Callahan, B.J. (2018). Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome, 6.","DOI":"10.1186\/s40168-018-0605-2"},{"key":"ref_62","first-page":"21","article-title":"Estimating the size of treatment effects: Moving beyond p values","volume":"6","author":"McGough","year":"2009","journal-title":"Psychiatry"},{"key":"ref_63","unstructured":"Cohen, J. (1989). Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum Associates. [2nd ed.]."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Morales, C., Rojas, G., Rebolledo, C., Rojas-Herrera, M., Arias-Carrasco, R., Cuadros-Orellana, S., and Saavedra, N. (2022). Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.943609"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2098293","DOI":"10.1155\/2017\/2098293","article-title":"Fecal calprotectin: A reliable predictor of mucosal healing after treatment for active ulcerative colitis","volume":"2017","author":"Kristensen","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","article-title":"Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes","volume":"19","author":"Schoepfer","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Chen, F., Hu, Y., Fan, Y.H., and Lv, B. (2021). Clinical value of fecal calprotectin in predicting mucosal healing in patients with ulcerative colitis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.679264"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.cgh.2020.08.019","article-title":"Diagnostic accuracy of fecal calprotectin concentration in evaluating therapeutic outcomes of patients with ulcerative colitis","volume":"19","author":"Stevens","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Man, A.W., Zhou, Y., Xia, N., and Li, H. (2020). Involvement of gut microbiota, microbial metabolites, and interaction with polyphenol in host immunometabolism. Nutrients, 12.","DOI":"10.3390\/nu12103054"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1039\/C8FO00468D","article-title":"Impact of tart cherry juice on systolic blood pressure and low-density lipoprotein cholesterol in older adults: A randomized controlled trial","volume":"9","author":"Chai","year":"2018","journal-title":"Food Funct."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cgh.2019.07.052","article-title":"Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study","volume":"18","author":"Jess","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/archdischild-2011-300633","article-title":"Association of pediatric inflammatory bowel disease with other immune-mediated diseases","volume":"96","author":"Kappelman","year":"2011","journal-title":"Arch. Dis. Child."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/apa.15643","article-title":"Comorbidity of inflammatory bowel disease in children and adolescents with type 1 diabetes","volume":"110","author":"Binder","year":"2021","journal-title":"Acta Paediatr."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Khademi, Z., Milajerdi, A., Larijani, B., and Esmaillzadeh, A. (2021). Dietary intake of total carbohydrates, sugar and sugar-sweetened beverages, and risk of inflammatory bowel disease: A systematic review and meta-analysis of prospective cohort studies. Front. Nutr., 8.","DOI":"10.3389\/fnut.2021.707795"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcmgh.2023.05.001","article-title":"Excess dietary sugar alters colonocyte metabolism and impairs the proliferative response to damage","volume":"16","author":"Burr","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1108\/00346650810891414","article-title":"Effects of sour cherry juice on blood glucose and some cardiovascular risk factors in diabetic women: A pilot study","volume":"38","author":"Hosseini","year":"2008","journal-title":"Nutr. Food Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00394-020-02355-5","article-title":"Effects of short-term continuous Montmorency tart cherry juice supplementation in participants with metabolic syndrome","volume":"60","author":"Desai","year":"2021","journal-title":"Eur. J. Nutr."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/2\/306\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:36:10Z","timestamp":1760027770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/2\/306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":77,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["life15020306"],"URL":"https:\/\/doi.org\/10.3390\/life15020306","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]}}}